Literature DB >> 20577849

Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate.

Yoshikazu Shimomura1, Shiro Higaki, Keizo Watanabe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577849     DOI: 10.1007/s10384-010-0803-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


× No keyword cloud information.
  16 in total

1.  Reactivation and latency of herpesvirus in the eye.

Authors:  Y Shimomura
Journal:  Ophthalmologica       Date:  2001       Impact factor: 3.250

2.  Corneal buttons obtained from patients with HSK harbor high copy numbers of the HSV genome.

Authors:  Yoshikazu Shimomura; Tatsunori Deai; Masahiko Fukuda; Shiro Higaki; Laura C Hooper; Kozaburo Hayashi
Journal:  Cornea       Date:  2007-02       Impact factor: 2.651

3.  9-(4-Hydroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, suppresses herpes virus reactivation in mice.

Authors:  B M Gebhardt; G E Wright; H Xu; F Focher; S Spadari; H E Kaufman
Journal:  Antiviral Res       Date:  1996-05       Impact factor: 5.970

4.  Propranolol suppression of ocular HSV-1 recurrence and associated corneal lesions following spontaneous reactivation in the rabbit.

Authors:  H E Kaufman; E D Varnell; B M Gebhardt; H W Thompson; J M Hill
Journal:  Curr Eye Res       Date:  1996-06       Impact factor: 2.424

5.  Role of Stat4-mediated signal transduction events in the generation of aggressor CD4+ T cells in herpetic stromal keratitis pathogenesis.

Authors:  Kaustuv Banerjee; Partha S Biswas; Barry T Rouse
Journal:  J Interferon Cytokine Res       Date:  2007-01       Impact factor: 2.607

6.  Bupropion (Zyban, Wellbutrin) inhibits nicotine-induced viral reactivation in herpes simplex virus type 1 latent rabbits.

Authors:  Marvin E Myles; Ann M Azcuy; Ngoc T Nguyen; Eric R Reisch; Steven A Barker; Hilary W Thompson; James M Hill
Journal:  J Pharmacol Exp Ther       Date:  2004-07-13       Impact factor: 4.030

7.  Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.

Authors:  Herbert E Kaufman; Emily D Varnell; Bryan M Gebhardt; Hilary W Thompson; Ephraim Atwal; Helga Rübsamen-Waigmann; Gerald Kleymann
Journal:  J Ocul Pharmacol Ther       Date:  2008-02       Impact factor: 2.671

8.  ATF/CREB elements in the herpes simplex virus type 1 latency-associated transcript promoter interact with members of the ATF/CREB and AP-1 transcription factor families.

Authors:  S Millhouse; J J Kenny; P G Quinn; V Lee; B Wigdahl
Journal:  J Biomed Sci       Date:  1998 Nov-Dec       Impact factor: 8.410

9.  Inhibition by indomethacin of in vitro reactivation of latent herpes simplex virus type 1 in murine trigeminal ganglia.

Authors:  I Kurane; Y Tsuchiya; T Sekizawa; K Kumagai
Journal:  J Gen Virol       Date:  1984-10       Impact factor: 3.891

10.  Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.

Authors: 
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

View more
  3 in total

1.  Effects of antiviral medications on herpetic epithelial keratitis in mice.

Authors:  Shohei Komoto; Shiro Higaki; Masahiko Fukuda; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2015-02-25       Impact factor: 2.447

2.  DLK-Dependent Biphasic Reactivation of Herpes Simplex Virus Latency Established in the Absence of Antivirals.

Authors:  Sara Dochnal; Husain Y Merchant; Austin R Schinlever; Aleksandra Babnis; Daniel P Depledge; Angus C Wilson; Anna R Cliffe
Journal:  J Virol       Date:  2022-05-24       Impact factor: 6.549

3.  A Hsp40 chaperone protein interacts with and modulates the cellular distribution of the primase protein of human cytomegalovirus.

Authors:  Yonggang Pei; Wenmin Fu; Ed Yang; Ao Shen; Yuan-Chuan Chen; Hao Gong; Jun Chen; Jun Huang; Gengfu Xiao; Fenyong Liu
Journal:  PLoS Pathog       Date:  2012-11-01       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.